Priority review to NDA for the investigational oncology compound radium-223 dichloride
Bayer HealthCare announced today that the US Food and Drug Administration (FDA) has granted priority review to the New Drug...
Information on this website is exclusively for health care professionals and not the general public.
Are you a qualified Secondary-Care Pharmacist or healthcare professional?


